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Abstract
Several studies have detected human papilloma virus (HPV) DNA in squamous cell carcinoma of the oesophagus (OSCC). In this study, we
analysed OSCC specimens from 114 patients for the presence of HPV DNA, and p53 and p73 expression. HPV DNA was detected in 44.7% of
cases, with the low risk HPV11 occurring most frequently. p53 and p73 expression was detected in 70% and 61.4% of cases, respectively. There
was no correlation between expression of p53, p73 or HPV infection and tumour grade, or between p53 expression and the presence of HPV DNA.
There was, however, significant correlation between p73 expression and the presence of HPV DNA (pb0.01) and p53 and p73 co-expression
(pb0.001), as well as co-expression of p53 and p73 with HPV status (pb0.05). These data support previous studies suggesting a role for HPV
infection in OSCC and also indicate that HPV infection and p53 and p73 overexpression are not mutually exclusive. In addition, the data implicate
a role for p73 in OSCC and suggest a complex interaction between p53, p73 and HPV in the aetiology of the disease.
© 2007 Elsevier Inc. All rights reserved.Keywords: Oesophageal cancer; Human papilloma virus; p53; p73Introduction
Oesophageal cancer is the eighth most common cancer in the
world with a worldwide incidence rate of 11.5/100 000
(GLOBOCAN 2002 database-www-dep.iarc.fr/) (Ferlay et al.,
2002). One of the features of squamous cell carcinoma of the
oesophagus is the fragmentation of its incidence into low risk
and high risk areas, based on geographical location. Some of the
low risk areas include North America, countries in Western Asia
and Northern and Southern Europe, where the incidence rates
range from 1.5 to 6.0/100,000 and well defined high risk areas
such as South Africa, China, Iran and countries in Eastern
Africa, where the incidence rates range from 10 to 25/100,000
(Ferlay et al., 2002). Furthermore, within these high risk areas,
there are regions, such as the Transkei region in South Africa⁎ Corresponding author. Fax: +27 21 4066060.
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doi:10.1016/j.virol.2007.07.025(Hendricks and Parker, 2002) and northern parts of China,
where the incidence rates are substantially higher.
The risk factors involved in the aetiology of the disease and
the reasons for the geographical variation are poorly under-
stood, but it is known that factors that cause inflammation and
chronic irritation to the oesophagus increase the risk of
squamous cell carcinoma. Multiple factors such as alcohol
and tobacco consumption, nutritional deficiencies, socioeco-
nomic status and chemicals such as nitrosamines have been
implicated (Brown et al., 2001; Enzinger and Mayer, 2003). The
genetic disorder, tylosis, characterised by an abnormality at
chromosome 17q25 also confers increased risk to OSCC;
however, this is rare (Ellis et al., 1994; Risk et al., 1999).
Numerous studies have detected human papillomavirus
(HPV) DNA in oesophageal cancer specimens, implicating
HPV infection as a further risk factor in the development of
OSCC (de Villiers et al., 2004; Syrjanen, 2002). The frequency
of detection of HPV DNA in OSCC is highly variable, ranging
from 0 to 70%. This variability in detection rates may reflect the
183T. Matsha et al. / Virology 369 (2007) 182–190different methodologies used in the different studies. Interest-
ingly, the highest frequencies of HPV infection are seen in the
high risk geographical locations. HPV infection has been
implicated in other squamous cell carcinomas such as head and
neck cancer (Fakhry and Gillison, 2006), and non-melanoma
skin cancer (Accardi et al., 2006; Harwood et al., 2000; Kiviat,
1999), and its involvement in cervical cancer is well established
(Woodman et al., 2007).
In cervical cancer, the E6 and E7 proteins from high risk
HPV types are required for the induction and maintenance of the
transformed phenotype. E6 complexes with p53 and targets it
for degradation (Band et al., 1993; Havre et al., 1995; Li and
Coffino, 1996; Scheffner et al., 1993) while the E7 oncoprotein
inactivates the retinoblastoma (Rb) tumour suppressor and its
family members, thereby interfering with their control of the
G1/S transition of the cell cycle (Dyson et al., 1989; Liu et al.,
2006; Ueno et al., 2006). In addition to inactivating these two
classical tumour suppressor genes, HPV-E6 also inactivates
p73, a close family member of p53 whose biological activity
closely mimics that of p53 (Moll and Slade, 2004; Park et al.,
2001) while HPV-E7 transactivates it, suggesting a role for p73
in the transformation process of cervical epithelial cells (Brooks
et al., 2002).
The role that HPV-E6 and E7 play in oesophageal cancer
with respect to p53 inactivation is not clear. A wide range of
HPV types, including both high risk and low risk types, are
associated with oesophageal cancer (Syrjanen, 2002) and p53
expression is significantly correlated with high risk HPV-E6
expression (Qi et al., 2006). p53 mutation, however, does not
correlate with HPV infection (Chang et al., 1994; Shibagaki et
al., 1995), suggesting that while HPV infection and p53
mutation may frequently be involved in oesophageal cancer,
they are not associated with one another. There is some
evidence to suggest an association with the polymorphism in
codon 72 of p53 with HPV-associated oesophageal cancer, with
the Arg homozygous genotype occurring more frequently than
in HPV negative tumours and being more susceptible to
degradation by HPV16/18-E6 (Kawaguchi et al., 2000; Li et al.,
2002). This, however, is still controversial since a further study
from a high risk area in China found no correlation between theTable 1













The L1 region was amplified by nested PCR using the degenerate MY09/MY11 prime
was amplified using the WD primers.
a M, A+C; R, A+G; W, A+T; Y, C+T; S, G+C.p53 codon 72 polymorphism and HPV infection (Peixoto
Guimaraes et al., 2001). At present there is no evidence linking
HPV infection with p73 expression in oesophageal cancer;
however, overexpression of p73 has been found in squamous
cell carcinomas of the oesophagus (Cai et al., 2000).
We have previously identified the presence of HPV DNA in
OSCC samples from the high risk Transkei region of South
Africa (Matsha et al., 2002). In the present study, we examined
the correlation between p53 and p73 levels and the presence of
HPV DNA. No correlation was found between p53 and p73
levels and tumour grade when these parameters were analysed
individually, or between p53 expression and the presence of
HPV DNA. p73 levels were, on the other hand, significantly
higher in HPV DNA positive tumours than in HPV negative
tumours. In addition, there was a strong correlation between co-
expression of p53 and p73 and the presence of HPV DNA. The
results suggest that HPV is associated with a subset of
oesophageal cancers and that there may be a complex
interaction between p53, p73 and HPV in the aetiology of
some oesophageal tumours.
Results
Detection of HPV DNA in OSCC
PCR amplification with the consensus degenerate primers to
the L1 and E6 genes was used to detect human papillomavirus
(HPV) DNA in the 114 OSCC and 41 normal oesophageal
samples. HPV DNAwas detected in 52 of the 114 (46%) OSCC
samples and only 3 (7.3%) of the normal samples. Thirty-two of
the HPV DNA positive OSCC samples were positive for both
genes and 20 were positive for the L1 gene only. All 3 of the
HPV positive normal samples were positive for the L1 gene
only. One possible explanation for this is that not all types of
HPV will be detected by the E6 primers due to limitations in
their design. All of the samples were positive for the β-actin
control using the β-actin primers indicated in Table 1. DNA
sequence analysis revealed the presence of multiple HPV types
in the OSCC samples with HPV11 being present in 22 cases,
HPV16 in 6 cases, HPV39 in 9 cases and HPV 52 in 4 cases.Gene Tm PCR product
L1 55 °C 450 bp
L1 40 °C 150 bp
E6 55 °C 240 bp
β-actin 57 °C 650 bp
rs for the first reaction and the GP5+/GP6+ for the second reaction. The E6 gene
Table 3
Summary of the tumour grade, presence of HPV DNA and p53 and p73
expression of the oesophageal squamous cell carcinomas analysed (n=114)
Histology a HPV DNA p53 p73
Negative Positive Negative Positive Negative Positive
Poor 13 b 8 6 15 9 12
Moderate 42 30 24 48 31 41
Well 8 13 4 17 4 17
Total 63 51 34 80 44 70
a Poor: poorly differentiated; moderate: moderately differentiated; well: well
differentiated.
b Number of patients.
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not match any published sequences and were thus termed
unclassified (Table 2). In addition, none of the samples
contained multiple sequences, indicating that single cancer
specimens did not contain DNA from multiple HPV types.
None of the high risk types was detected in the normal samples
(Table 2). No viral particles were detected immunohistochemi-
cally using an antibody that cross reacts with the major capsid
protein of HPV 6, 11, 16, 18, 31, 33, 42, 51, 52, 56 and 58
(Dako, Clone K1H8) (data not shown) indicating an absence of
virus production. The OSCC samples were classified as well
differentiated (21/114), moderately differentiated (72/114) and
poorly differentiated (21/114), with no statistically significant
difference between HPV status and tumour grade (p=0.2)
(Table 3).
Analysis of p53 levels in OSCC
One of the mechanisms by which HPV contributes to cell
transformation is by E6-mediated degradation of p53. Thus to
determine whether there was a correlation between p53
expression and HPV status in our tumour samples, we analysed
the levels of p53 by immunohistochemistry. Staining intensity
was scored by two independent histopathologists as 1+(10–
25% of nuclei staining positive), 2+ (25–50% positive nuclei)
or 3+(N50% positive nuclei) in five fields of view under low
magnification. There was complete agreement in all but one
case; however, consensus was reached after discussion and
review of the case. Seventy percent of the tumour specimens
had detectable levels of p53 (Fig. 1) while intense staining
was observed in 58.7% of the samples (2+staining in 10.5%
and 3+staining in 48.2% of the samples). Staining was restricted
to the carcinoma as less than 10% of cells in the adjacent normal
tissue stained positive for p53. There was no statistically
significant correlation between p53 staining and tumour grade
(p=0.44) (Table 3).
Analysis of p73 levels in OSCC
p73 is a close family member of p53 and is also thought to
have tumour suppressor activity. Since no correlation was
observed between p53 expression and HPV status, we
examined whether there was an association between the levels
of p73 and HPV status. As for p53, p73 levels were determinedTable 2
Summary of HPV DNA identified in squamous cell carcinoma of the
oesophagus and normal oesophageal tissue
HPV Type OSCC (n=114) Normal (n=41)
Negative 62 (54.4) a 38 (92.7)
HPV11 22 (19.3) 1 (2.4)
HPV16 6 (5.3) 0 (0)
HPV39 9 (7.9) 1 (2.4)
HPV52 4 (3.5) 0 (0)
Unclassified 11 (9.6) 1 (2.4)
PCR positive samples were sequenced to identify the HPV type.
a Percentage of the total.by immunohistochemistry using the same criteria as described
above. p73 staining was more diffuse than that observed for p53
and localised to the nucleus (Fig. 2). p73 expression was
elevated in tumour cells compared to the surrounding normal
tissue in 61.4% of the samples. p73 was detectable in the
neighbouring normal epithelia in only 2 cases, and this
reactivity was restricted to the nuclei of the cells closest to
and within the basal layer. There was no significant correlation
between p73 levels and tumour grade (p=0.1) (Table 3).
Correlation between HPV DNA, p53 and p73 levels
In order to assess the relationship between the presence of
HPV DNA and p53 and p73 levels, the three variables were
analysed to determine whether there existed any correlation
between them. There was a strong positive correlation (Rs=0.6)
between the staining intensity of p53 and p73 in all the tumour
samples (Fig. 3A). Furthermore, there was a significant
correlation between the co-expression of p53 and p73 in tumour
samples (pb0.001) (Fig. 3B). Thirty-two percent of the tumour
samples had undetectable or low (1+) levels of both proteins and
39% had high (2+ and 3+) levels of both proteins (Fig. 3B). The
remaining 29% of samples had either low p53 and high p73 or
high p53 and low p73 levels (Fig. 3B). There was no significant
correlation (p=0.4) between co-expression of p53 and p73 and
tumour grade. There was also no significant correlation between
p53 staining and HPV DNA (p=0.2) (Fig. 4A). Interestingly, of
those tumours positive for the high risk HPV 16, the majority of
the samples had low p53 levels unlike in tumours positive for the
low risk HPV types where the majority of the samples had high
levels of p53 staining. This observation, however, was not
statistically significant due to small sample numbers. While
there was no significant correlation between p53 expression and
HPV DNA, there was a statistically significant correlation
between p73 protein levels and the presence of HPV DNA
(pb0.01) (Fig. 4A). As for p53, the majority of tumours that
were positive for HPV 16 had low p73 levels compared to the
tumours positive for the other HPV types, of which the majority
had high p73 levels. Again, this observation was not statistically
significant due to the small number of samples, but it may
suggest an interplay between HPV 16 and both p53 and p73 in
the development of oesophageal cancer. p53 and p73 co-
expression was also significantly correlated with the presence of
HPV DNA (pb0.05) (Fig. 4B). The majority of HPV DNA
Fig. 1. p53 expression in oesophageal squamous cell carcinoma. p53 expression was analysed by immunohistochemistry as described in Materials and methods. The
figure shows representative sections of a p53 negative tumour (A), and samples staining weakly (+1) (B), moderately (+2) (C) and strongly (+3) (D) for p53. All
sections shown are 200× magnification, with the exception of panel D, 100× magnification.
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sion of p53 and p73, while in the HPV DNA negative samples
there was a higher frequency of p53/p73 negative and
p53positive/p73negative samples (Fig. 4B).
Discussion
South Africa, and in particular, the Transkei region, is an area
with a high incidence of oesophageal cancer. Amongst the risk
factors associated with this disease are alcohol consumption,
smoking and exposure to chemicals such as nitrosamines. A
number of studies have also implicated HPV infection in the
pathogenesis of oesophageal cancer (Chang et al., 1990; He et
al., 1997; Matsha et al., 2002; Toh et al., 1992; Williamson et al.,
1991). The frequency with which HPV is detected in
oesophageal cancer varies from less than 10% to approximately
70% of cases, depending on the detection technique used
(Syrjanen, 2002). We have previously identified HPV DNA in
46% of OSCC specimens from the high risk Transkei region in
South Africa (Matsha et al., 2002) and in this study this figure
has been confirmed using a larger cohort of patients. While HPV
DNA is clearly evident in a number of OSCC specimens, the
exact role of HPVinfection in OSCC remains controversial, with
some studies suggesting that there is no association between
HPV infection and neoplastic progression of oesophageal cancer
(Gao et al., 2006) or survival of oesophageal patients (Dreilich etal., 2006), while others support a role for HPV infection in the
pathogenesis and prognosis of oesophageal cancer (Furihata et
al., 1993; He et al., 1997; Si et al., 2005).
We identified a number of different HPV types in the present
study, with the most frequent being the low risk HPV11
occurring in 43% of the HPV positive samples. This is in
agreement with our previous study which also identified HPV11
as the major type associated with OSCC patients from the
Transkei region (Matsha et al., 2002). The high risk HPV16
occurred at a much lower frequency, with 12% of the HPV
positive tumour samples being positive for this type. These data
are in agreement with other studies, which also showed a
prevalence for HPV11 in oesophageal cancer (de Villiers et al.,
2004). Unlike the high risk HPV16 and 18, which are causative
for cervical cancer (Woodman et al., 2007), little is known about
the effects of low risk HPV types, such as HPV11, on cell
transformation. Evidence suggests that the transforming
proteins from the different types do not function in the same
manner. Oncogenic HPV E6 complexes with, amongst others,
the human homologue of the Drosophila tumour suppressor
Dlg and targets it for degradation correlating with the oncogenic
potential of these viruses. The HPV11 E6 protein, however, is
unable to bind and target Dlg for degradation (Gardiol et al.,
1999). In addition, the E2 proteins from high and low risk types
differ in their ability to bind p53 (Parish et al., 2006). There is
also evidence to suggest that the transforming proteins from the
Fig. 2. p73 expression in squamous cell carcinoma of the oesophagus. p73 expression was analysed by immunohistochemistry as described in Materials and methods.
(A); p73 expression in the surrounding normal epithelium is confined to the basal layer, (B), non-specific background using the secondary antibody only, (C)
representative section showing moderate (2+) p73 expression and (D) representative section showing high (3+) p73 expression. All sections shown are 100×
magnification, with the exception of panel C, 200× magnification.
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high risk types, including episomal maintenance of the viral
genome (Oh et al., 2004).
The high risk HPV E6 proteins bind to and target p53 for
degradation (Band et al., 1993; Havre et al., 1995; Li and
Coffino, 1996; Scheffner et al., 1993). In our tumour samples,
there was no statistically significant correlation between p53
expression and HPV infection, as assessed by the presence of
HPV DNA. Elevated levels of p53 were found in approximately
60% of our tumour samples, suggesting that HPV infection and
p53 overexpression are not mutually exclusive. Aberrant
expression of p53 has been detected in oesophageal cancer
(Chang et al., 1997; Furihata et al., 1993; Lee et al., 2006) and is
implicated as a poor prognostic indicator of oesophageal cancer
(Cao et al., 2004; Furihata et al., 1993). Our results showing
60% of OSCC samples with elevated p53 levels support this.
Elevated levels of p53 in oesophageal cancer has also been
found to be influenced by prolonged exposure to environmental
factors such as cigarette smoke and alcohol (Lee et al., 2006),
thus in our patient population, exposure to similar environ-
mental factors may result in p53 overexpression.
Interestingly, the tumour samples with HPV16 DNA showed
a higher frequency of low or undetectable levels of both p53 and
p73 compared to both HPV negative tumours and those thatwere positive for low risk HPV types, although the sample
numbers were too low to reach significance. The same portion of
HPV E6 is responsible for the inactivation of both p53 and p73
function (Park et al., 2001) and HPV16/18 E6 has been
implicated in poor prognosis of oesophageal cancer patients
(Furihata et al., 1993). Taken together, these data suggest that
high risk HPV types may contribute to oesophageal cancer by
E6-mediated inactivation of both p53 and p73 and implicate
these HPV types as an aetiological factor for oesophageal cancer.
In addition to aberrant p53 expression, we also detected
overexpression of p73 in 61% of our cancer specimens
compared to the adjacent normal tissue. p73 has been found
to be overexpressed in numerous tumour types, including breast
(Dominguez et al., 2006; Zaika et al., 1999), lung (Tokuchi et
al., 1999), gastric (Kang et al., 2000), colon (Dominguez et al.,
2006; Sun, 2002), bladder (Chi et al., 1999; Yokomizo et al.,
1999), ovarian (Chen et al., 2000; Ng et al., 2000), liver
(Tannapfel et al., 1999) and oesophageal (Cai et al., 2000)
cancer. High p73 levels are a prognostic factor correlating with
poorer survival compared to undetectable p73 (Sun, 2002;
Tannapfel et al., 1999). The functional significance of p73 up-
regulation remains unclear, but it may, in combination with
other aberrantly expressed proteins, stimulate cell growth. It has
recently been reported that p73 synergises with the proto-
Fig. 3. Correlation between the levels of p53 and p73 expression in squamous
cell carcinoma of the oesophagus. p53 and p73 were detected immunohisto-
chemically and levels were scored as absent (0), low (1+), moderate (2+) or high
(3+) as described (A). The staining intensity of both p53 and p73 showed a
strong positive correlation. The samples (n=114) were also divided into four
groups according to their pattern of staining for both p53 and p73 in combination
as indicated on the figure (B). There was a significant correlation (pb0.001)
between co-expression of p53 and p73 as determined by chi-squared analysis.
Fig. 4. Correlation between the presence of HPV DNA and expression of p53
and p73. Samples were divided into four groups as indicated on the figures
according to the absence or presence of p53 and p73 individually (A) or in
combination (B), and assessed for their association with HPV DNA. Chi-
squared analysis revealed significant relationships between the expression of
p73 and the presence of HPV DNA (pb0.01) and the co-expression of p53 and
p73 and HPV DNA (pb0.05). There was no significant correlation between p53
expression and the presence of HPV DNA (p=0.2).
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1, a transcriptional complex that contributes to transformation
and tumour aggressiveness (Vikhanskaya et al., 2007). In
oesophageal cancer, p73 overexpression is suggested to be a
compensatory mechanism for defective p53. Our data presented
here cannot exclude this possibility since we found a significant
correlation between p53 and p73 co-expression; however, we
did not analyse the mutational status of p53 in our samples,
although analysis of a smaller cohort of OSCC patients from the
same geographical region showed a low frequency (8%) of p53
mutations (unpublished data). Other studies in oesophageal
cancer patients from South Africa have also found a low
frequency of p53 mutations (Gamieldien et al., 1998; Vos et al.,
2003), supporting our unpublished observations. We also found
a significant correlation between p73 expression and the
presence of HPV DNA. A number of possibilities exist to
explain this finding. Firstly, p73 physically interacts with E6
from both HPV16 and HPV11 resulting in inactivation of p73
(Park et al., 2001). This inactivation is different from E6-
mediated inactivation of p53 since it does not involve its
subsequent degradation (Park et al., 2001). Secondly, E6 and E7
from the cutaneous human papilloma virus HPV38 induce
stabilisation of wild type p53 which consequently results in the
upregulation of an isoform of p73 that inhibits the p53-mediated
transcription of genes involved in apoptosis and growth
suppression (Accardi et al., 2006). These findings may explain
the significant correlation between the co-expression of p53 andp73 and HPV positive cancers in our study. Further studies are
necessary to fully elucidate the significance and consequence of
the correlation between p53 and p73 expression and HPV
infection in oesophageal cancer.
In summary, we found the presence of HPV DNA in a high
frequency of OSCC in patients from the high risk Transkei region
in South Africa. The high prevalence of low risk HPV types in
oesophageal cancer warrants further studies on possible interac-
tions with other risk factors associated with OSCC such as
smoking, alcohol consumption and the nutritional deficiencies
associated with this region. In addition, both p53 and p73 were
overexpressed in the majority of these tumours, and there was a
significant correlation between p73 overexpression and HPV
DNA positive tumours, as well as p53 and p73 co-expression and
the presence of HPV DNA. These data suggest an association
between HPV infection and oesophageal cancer and support the
idea of a complex interaction between p53, p73 and HPV.
Materials and methods
Tissues
One hundred and fourteen paraffin embedded biopsies of
histologically confirmed squamous cell carcinoma of the
188 T. Matsha et al. / Virology 369 (2007) 182–190oesophagus and 41 paraffin embedded histologically normal
sections were obtained from archival material in the department
of Anatomical Pathology at the Umtata General Hospital, South
Africa. Ethical approval for this study was obtained from the
Ethics Committees of the Universities of Transkei and Cape
Town. Consecutive 3 μm sections were prepared from each
biopsy and one section was stained with haematoxylin–eosin to
confirm the initial diagnosis using the World Health Organisa-
tion (WHO) TNM classification system. In addition, the
tumours were graded as well differentiated, moderately
differentiated and poorly differentiated. The remaining sections
were placed in a sterile microfuge tube for DNA isolation.
Detection and typing of HPV DNA
PCR amplification of HPV DNA from paraffin sections was
conducted on the 114 biopsies as previously described (Matsha
et al., 2002). Briefly, paraffin sections were incubated overnight
at 37 °C in digestion buffer containing 1% Tween-20 and
200 μg/ml proteinase K. Proteinase K was heat-inactivated at
95 °C for 10 min prior to PCR amplification. Degenerate
consensus primers were used to amplify the HPV E6 gene to
produce a 240 bp PCR product (Matsha et al., 2002; Park et al.,
2001). Sequences from the HPV L1 gene were amplified by
nested PCR using the MY09/MY11 consensus primer set in the
first amplification step to produce a 400 bp fragment and the
GP5+/GP6+ primer set in the second step to produce a 150 bp
PCR product. Human β-actin was used as an internal control to
produce a 640 bp PCR product (see Table 1 for all primer
sequences, and PCR product sizes). Template DNA was
incubated in 1× PCR buffer containing 0.05 mM dNTPs, 10–
100 pmol of each primer and 2.5 U Taq DNA polymerase. PCR
reactions were carried out in a final volume of 50 μl for 40
cycles of 1 min denaturation (94 °C), 1 min annealing (see Table
1 for annealing temperatures) and 1 min extension (72 °C)
followed by a final extension for 5 min at 72 °C. PCR products
were separated by agarose gel electrophoresis and visualised
under UV light after staining with ethidium bromide. The PCR
products from all the positive samples were subjected to DNA
sequence analysis. Similarity searches between the nucleotide
sequences and those published in sequence databases were done
using BLAST (www.ncbi.nlm.nih.gov/BLAST) to determine
the HPV type.
Immunohistochemistry
Paraffin sections were dewaxed using standard procedures.
Briefly, sections were incubated in a pressure cooker in
10 mM citrate buffer (pH 6.2) (for p53) or EDTA (pH 8.0) (for
p73) for 2 min for antigen retrieval. Endogenous peroxidase
activity was blocked by incubation in 1% hydrogen peroxide
for 30 min. Sections were then incubated with normal goat
serum for 30 min to block non-specific binding, followed by
incubation for 1 h (p53) or overnight (p73) at 4 °C with anti-
p53 antibody (DO-7, Dako), diluted 1:50 or anti-p73 (sc-7957,
Santa Cruz), diluted 1:200 in antibody diluent (Dako).
Sections were washed with phosphate buffered saline andthe signal was detected using the Envision detection system
(Dako) with Diaminobenzene (DAB-substrate chromagen,
Dako) as substrate. After the colour had developed, the
sections were washed in water, lightly counterstained with
haematoxylin, dehydrated in alcohol, cleared in xylene and
mounted in Entelan (Merck).
Statistical analysis
Statistical comparisons of the data were done with chi-square
and Spearman's rank correlation tests and correlations were
considered significant at pb0.05.
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